神經生物標記物市場規模、佔有率、成長分析、按類型、按應用、按最終用戶、按地區 - 行業預測，2024-2031 年

2022年神經生物標記市場規模預計為61.3億美元，預測期內（2024-2031年）複合年成長率為13.6%，從2023年的69.6億美元增至2031年的193.1億美元。

全球神經生物標記市場預計將大幅擴張，主要是由於阿茲海默症、帕金森氏症和多發性硬化症等神經系統疾病的盛行率不斷上升，以及對精確診斷工具的需求不斷增加。世界老化和生活方式的改變正在增加這些疾病的盛行率，並增加了對有效診斷的需求，以便進行早期療育和加強疾病管理。神經生物標記推動了向精準醫療和標靶治療的轉變，神經生物標記使醫療保健提供者能夠根據個人的遺傳和分子特徵客製化治療方案，最佳化結果，同時最大限度地減少副作用，這進一步加速了對神經生物標記的需求。然而，由於神經系統疾病的複雜性，他們面臨挑戰，使可靠生物標記的識別和檢驗變得複雜。確定生物標記的敏感性、特異性和預測價值需要廣泛的研究和臨床試驗，這通常會導致一個耗時且昂貴的過程。此外，研究人員和醫療保健專業人員必須仔細考慮與生物標記開發相關的監管和道德問題，例如確保患者隱私和知情同意。生物標記測定和資料解釋缺乏標準化是另一個障礙，因為實驗室技術的不一致可能會妨礙研究之間的可比較性。話雖如此，美國神經生物標記市場正處於穩健的軌道上，預計在接下來的預測期內將出現持續成長和充滿希望的機會。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 技術分析
• 管道分析
• 滲透率和成長前景分析
• PESTEL分析
• 專利分析

神經生物標記市場：按類型

• 市場概況
• 基因組
• 蛋白質體
• 代謝體學
• 影像
• 其他

神經生物標記市場：依應用分類

• 市場概況
• 阿茲海默症
• 帕金森氏症
• 多發性硬化症
• 泛自閉症障礙
• 其他

神經生物標記市場：依最終用戶分類

• 市場概況
• 醫院和醫院實驗室
• 獨立臨床診斷中心
• 研究機構等

神經生物標記市場規模：按地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Quanterix Corporation
• Thermo Fisher Scientific Inc.
• Myriad Genetics, Inc.
• QIAGEN NV
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• F. Hoffmann-La Roche Ltd
• Bio-Techne Corporation
• Alector Inc.
• bioMerieux
• Charles River Laboratories International, Inc.
• Cisbio
• C2N Diagnostics
• ImmunArray
• Euroimmun AG
• Abbott Laboratories

Neurological Biomarkers Market size was valued at USD 6.13 Billion in 2022 and is poised to grow from USD 6.96 Billion in 2023 to USD 19.31 Billion by 2031, at a CAGR of 13.6% during the forecast period (2024-2031).

The global neurological biomarkers market is poised for significant expansion, driven primarily by the rising prevalence of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, alongside an increasing demand for precise diagnostic tools. The aging global population and lifestyle factors have resulted in a surge of these conditions, fueling the need for effective diagnostics that enable early intervention and enhanced disease management. The shift towards precision medicine and targeted therapies further accelerates the demand for neurological biomarkers, which allow healthcare providers to tailor treatments based on individual genetic and molecular profiles, thereby optimizing outcomes while minimizing adverse effects. However, the market confronts challenges stemming from the intricate nature of neurological diseases, which complicates the identification and validation of reliable biomarkers. Extensive research and clinical trials are necessary to determine the sensitivity, specificity, and predictive value of biomarkers, often leading to time-consuming and costly processes. Additionally, regulatory and ethical challenges related to biomarker development, such as ensuring patient privacy and informed consent, need careful consideration from both researchers and healthcare professionals. The lack of standardization in biomarker assays and data interpretation presents another hurdle, as inconsistencies in laboratory techniques can hinder comparability across studies. Nevertheless, with a robust market trajectory, the US neurological biomarkers sector is expected to witness sustainable growth and promising opportunities in the forthcoming forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Neurological Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Neurological Biomarkers Market Segmental Analysis

Global Neurological Biomarkers Market is segmented by Type, Application, End User and Region. Based on Type, the market is segmented into Genomic, Proteomic, Metabolomic, Imaging, Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder, Others. Based on End User, the market is segmented into Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa

Driver of the Neurological Biomarkers Market

The rising prevalence of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, serves as a critical market driver for the global neurological biomarkers market. With the aging population and lifestyle factors contributing to the surge in these conditions, there is an escalating demand for accurate, early diagnostic tools that can facilitate timely intervention and improve patient outcomes. Neurological biomarkers play a vital role in enhancing disease detection, monitoring progression, and evaluating treatment efficacy. As healthcare providers and researchers increasingly recognize the importance of personalized medicine, the need for innovative biomarkers to support tailored therapeutic approaches further propels market growth in this sector.

Restraints in the Neurological Biomarkers Market

One of the significant market restraints for the neurological biomarkers industry is the extensive and resource-intensive process required for their discovery and validation. This involves conducting comprehensive research and lengthy clinical trials that not only demand substantial financial investment but also extended timelines, which can impede the speed of bringing these innovations to market. Consequently, the high costs associated with the development and validation of biomarkers can limit access to these advanced diagnostic and therapeutic options, making them less affordable for healthcare providers and patients alike. This financial barrier may hinder the widespread adoption of neurological biomarkers in clinical practice, ultimately affecting market growth.

Market Trends of the Neurological Biomarkers Market

The Neurological Biomarkers market is witnessing a significant trend towards the integration of Artificial Intelligence (AI) and Machine Learning (ML) technologies, which are revolutionizing biomarker research and data analysis. This shift enables the automation of data interpretation, thereby streamlining the identification of critical patterns and facilitating accurate predictions of disease outcomes. As a result, the efficiency and precision in the discovery and validation of neurological biomarkers are markedly improved. The increasing adoption of AI and ML not only accelerates research timelines but also enhances the overall reliability of diagnostics, reflecting a transformative movement that is poised to redefine approaches to neurological disorders.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Pipeline Analysis
• Penetration and Growth Prospects Analysis
• PESTEL Analysis
• Patent Analysis

Neurological Biomarkers Market, By Type

• Market Overview
• Genomic
• Proteomic
• Metabolomic
• Imaging
• Others

Neurological Biomarkers Market, By Application

• Market Overview
• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Autism Spectrum Disorder
• Others

Neurological Biomarkers Market, By End User

• Market Overview
• Hospital & Hospital Laboratories
• Independent clinical diagnostic centers
• Research Organizations and Others

Neurological Biomarkers Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Quanterix Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alector Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cisbio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C2N Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ImmunArray
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Euroimmun AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments